donepezil has been researched along with Disease Exacerbation in 96 studies
Donepezil: An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.
donepezil : A racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one : A member of the class of indanones that is 5,6-dimethoxyindan-1-one which is substituted at position 2 by an (N-benzylpiperidin-4-yl)methyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "APOE-ɛ4 and BCHE-K* positive subjects display an earlier age of onset of AD, an accelerated cognitive decline and a greater cognitive benefits to donepezil therapy." | 9.22 | Butyrylcholinesterase K and Apolipoprotein E-ɛ4 Reduce the Age of Onset of Alzheimer's Disease, Accelerate Cognitive Decline, and Modulate Donepezil Response in Mild Cognitively Impaired Subjects. ( De Beaumont, L; Dea, D; Lamarre-Théroux, L; Pelleieux, S; Poirier, J, 2016) |
| "The purpose of this study was to study the effect of donepezil on the rate of hippocampal atrophy in prodromal Alzheimer's disease (AD)." | 9.20 | Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer's disease. ( Ait Ameur, A; Bonafe, A; Cavedo, E; Ceccaldi, M; Chupin, M; Colliot, O; Croisile, B; Delmaire, C; Dormont, D; Dubois, B; Dufouil, C; Duveau, F; Garnero, L; Girard, N; Hampel, H; Lehericy, S; Lista, S; Louis Tisserand, G; Ousset, PJ; Pasquier, F; Ricolfi, F; Rouaud, O; Sarazin, M; Tonelli, I; Touchon, J; Vighetto, A, 2015) |
| "To evaluate the efficacy and safety of donepezil for severe Alzheimer disease (AD)." | 9.12 | Donepezil preserves cognition and global function in patients with severe Alzheimer disease. ( Black, SE; Doody, R; Jambor, KM; Li, H; McRae, T; Perdomo, CA; Richardson, S; Sun, Y; Xu, Y, 2007) |
| "To evaluate the effectiveness of donepezil compared with placebo in cancer patients with fatigue as measured by the Functional Assessment for Chronic Illness Therapy-Fatigue (FACIT-F)." | 9.12 | Donepezil for cancer fatigue: a double-blind, randomized, placebo-controlled trial. ( Bruera, E; Driver, LC; El Osta, B; Palmer, JL; Pei, BL; Poulter, VA; Shen, L; Valero, V, 2007) |
| "Donepezil treatment slows the progression of hippocampal atrophy, suggesting a neuroprotective effect of donepezil in Alzheimer's disease." | 9.11 | Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease? ( Hashimoto, M; Kazui, H; Matsumoto, K; Mori, E; Nakano, Y; Yasuda, M, 2005) |
| "Modulation of vagal tone using electrical vagal nerve stimulation or pharmacological acetylcholinesterase inhibition by donepezil exerts beneficial effects in an animal model of chronic heart failure (CHF)." | 7.80 | Adding the acetylcholinesterase inhibitor, donepezil, to losartan treatment markedly improves long-term survival in rats with chronic heart failure. ( Inagaki, M; Kawada, T; Li, M; Sugimachi, M; Uemura, K; Zheng, C, 2014) |
| "In this case-control study in patients with predominantly mild to moderate AD and related dementias, donepezil therapy prescribed in routine clinical practice was associated with reduced health care costs to the Medicare managed care plan studied." | 7.73 | Impact of donepezil use in routine clinical practice on health care costs in patients with Alzheimer's disease and related dementias enrolled in a large medicare managed care plan: a case-control study. ( Fillit, H; Hill, J; Lu, S, 2005) |
| "Donepezil administered at a prodromal stage of AD seems to substantially reduce the rate of atrophy of the BFCS nuclei with highest concentration of cholinergic neurons projecting to the cortex (NbM), hippocampus and entorhinal cortex (Ch1/2)." | 6.84 | Reduced basal forebrain atrophy progression in a randomized Donepezil trial in prodromal Alzheimer's disease. ( Cavedo, E; Chupin, M; Colliot, O; Dormont, D; Dubois, B; Grothe, MJ; Hampel, H; Houot, M; Lehéricy, S; Lista, S; Teipel, S, 2017) |
| "Treatment with donepezil did not alter the progression of hippocampal deformation in subjects with DAT in this study." | 5.36 | Donepezil treatment and changes in hippocampal structure in very mild Alzheimer disease. ( Csernansky, JG; Galvin, JE; Harms, MP; Morris, JC; Staggs, JM; Wang, L; Xiong, C, 2010) |
| "We determined the value of hippocampus (Hp) and basal forebrain (BF) volumes for predicting cognitive decline and treatment response in a double-blind, randomized, placebo-controlled phase 4 trial at 28 academic centers (France) in patients with amnestic mild cognitive impairment (MCI) receiving Donepezil 10 mg daily or placebo over 12 months, and 6 months open label follow-up." | 5.22 | Predictors of cognitive decline and treatment response in a clinical trial on suspected prodromal Alzheimer's disease. ( Bakardjian, H; Cavedo, E; Chupin, M; Colliot, O; Dormont, D; Dubois, B; Galluzzi, S; Grothe, MJ; Hampel, H; Lista, S; Teipel, SJ, 2016) |
| "APOE-ɛ4 and BCHE-K* positive subjects display an earlier age of onset of AD, an accelerated cognitive decline and a greater cognitive benefits to donepezil therapy." | 5.22 | Butyrylcholinesterase K and Apolipoprotein E-ɛ4 Reduce the Age of Onset of Alzheimer's Disease, Accelerate Cognitive Decline, and Modulate Donepezil Response in Mild Cognitively Impaired Subjects. ( De Beaumont, L; Dea, D; Lamarre-Théroux, L; Pelleieux, S; Poirier, J, 2016) |
| "The purpose of this study was to study the effect of donepezil on the rate of hippocampal atrophy in prodromal Alzheimer's disease (AD)." | 5.20 | Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer's disease. ( Ait Ameur, A; Bonafe, A; Cavedo, E; Ceccaldi, M; Chupin, M; Colliot, O; Croisile, B; Delmaire, C; Dormont, D; Dubois, B; Dufouil, C; Duveau, F; Garnero, L; Girard, N; Hampel, H; Lehericy, S; Lista, S; Louis Tisserand, G; Ousset, PJ; Pasquier, F; Ricolfi, F; Rouaud, O; Sarazin, M; Tonelli, I; Touchon, J; Vighetto, A, 2015) |
| "To determine whether the presence of depression predicts higher rate of progression to Alzheimer disease (AD) in patients with amnestic mild cognitive impairment (aMCI) and whether donepezil treatment beneficially affect this relationship." | 5.14 | Donepezil delays progression to AD in MCI subjects with depressive symptoms. ( Cummings, JL; Edland, SD; Lu, PH; Petersen, RC; Teng, E; Tingus, K, 2009) |
| "A 3-year, double-blind, placebo-controlled Alzheimer's Disease Cooperative Study initially designed to evaluate the efficacy of donepezil hydrochloride or vitamin E vs placebo to delay progression of MCI to dementia." | 5.12 | Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia. ( Clark, CM; DeCarli, C; Frisoni, GB; Grundman, M; Harvey, D; Jack, CR; Jin, S; Petersen, RC; Scheltens, P; Thal, LJ, 2007) |
| "To evaluate the efficacy and safety of donepezil for severe Alzheimer disease (AD)." | 5.12 | Donepezil preserves cognition and global function in patients with severe Alzheimer disease. ( Black, SE; Doody, R; Jambor, KM; Li, H; McRae, T; Perdomo, CA; Richardson, S; Sun, Y; Xu, Y, 2007) |
| "To evaluate the effectiveness of donepezil compared with placebo in cancer patients with fatigue as measured by the Functional Assessment for Chronic Illness Therapy-Fatigue (FACIT-F)." | 5.12 | Donepezil for cancer fatigue: a double-blind, randomized, placebo-controlled trial. ( Bruera, E; Driver, LC; El Osta, B; Palmer, JL; Pei, BL; Poulter, VA; Shen, L; Valero, V, 2007) |
| "Donepezil treatment slows the progression of hippocampal atrophy, suggesting a neuroprotective effect of donepezil in Alzheimer's disease." | 5.11 | Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease? ( Hashimoto, M; Kazui, H; Matsumoto, K; Mori, E; Nakano, Y; Yasuda, M, 2005) |
| "BChE-K polymorphisms are associated with deleterious changes in cognitive decline in MCI patients treated with donepezil for 3 years." | 3.85 | Deleterious Effect of Butyrylcholinesterase K-Variant in Donepezil Treatment of Mild Cognitive Impairment. ( Aisen, PS; Apostolova, LG; Chen, L; Li, X; Rissman, RA; Rotter, JI; Sokolow, S; Taylor, KD, 2017) |
| "AchEI therapy has no unfavorable effect on nutritional status or weight in elderly patients with different types of dementia, but it seems that food intake is better in those treated by rivastigmine patch." | 3.83 | Effects of Acetylcholinesterase Inhibitors on Nutritional Status in Elderly Patients with Dementia: A 6-month Follow-up Study. ( Isik, AT; Soysal, P, 2016) |
| "Modulation of vagal tone using electrical vagal nerve stimulation or pharmacological acetylcholinesterase inhibition by donepezil exerts beneficial effects in an animal model of chronic heart failure (CHF)." | 3.80 | Adding the acetylcholinesterase inhibitor, donepezil, to losartan treatment markedly improves long-term survival in rats with chronic heart failure. ( Inagaki, M; Kawada, T; Li, M; Sugimachi, M; Uemura, K; Zheng, C, 2014) |
| "In this case-control study in patients with predominantly mild to moderate AD and related dementias, donepezil therapy prescribed in routine clinical practice was associated with reduced health care costs to the Medicare managed care plan studied." | 3.73 | Impact of donepezil use in routine clinical practice on health care costs in patients with Alzheimer's disease and related dementias enrolled in a large medicare managed care plan: a case-control study. ( Fillit, H; Hill, J; Lu, S, 2005) |
| "Donepezil administered at a prodromal stage of AD seems to substantially reduce the rate of atrophy of the BFCS nuclei with highest concentration of cholinergic neurons projecting to the cortex (NbM), hippocampus and entorhinal cortex (Ch1/2)." | 2.84 | Reduced basal forebrain atrophy progression in a randomized Donepezil trial in prodromal Alzheimer's disease. ( Cavedo, E; Chupin, M; Colliot, O; Dormont, D; Dubois, B; Grothe, MJ; Hampel, H; Houot, M; Lehéricy, S; Lista, S; Teipel, S, 2017) |
| " ABT-126 was generally well tolerated; the most common adverse events were agitation, constipation, diarrhea, fall, and headache." | 2.82 | Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study. ( Florian, H; Gault, LM; Gauthier, S; Lin, Y; Lipschitz, S; Meier, A; Othman, AA; Robieson, WZ; Tang, Q, 2016) |
| "More donepezil-treated subjects (18." | 2.74 | Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial. ( Doody, RS; Ferris, SH; Goldman, R; Murthy, AK; Salloway, S; Sun, Y; Watkins, WE; Xu, Y, 2009) |
| "Patients with mild to moderate Alzheimer's disease received open-label treatment with donepezil (5 mg/day for 4 weeks, then 10 mg/day for the remainder of the phase) for 12-24 weeks." | 2.72 | Assessing therapeutic efficacy in a progressive disease: a study of donepezil in Alzheimer's disease. ( Hampel, H; Johannsen, P; Qvitzau, S; Richardson, S; Salmon, E; Schindler, R; Xu, Y, 2006) |
| " A cumulative dose-response relationship was observed between longer-term sustained donepezil use and delay of NHP." | 2.71 | Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. ( Geldmacher, DS; Ieni, JR; Mastey, V; McRae, T; Provenzano, G, 2003) |
| "Donepezil has demonstrated a range of effects, including protecting against amyloid β, ischaemia and glutamate toxicity; slowing of progression of hippocampal atrophy; and up-regulation of nicotinic acetylcholine receptors." | 2.55 | Beyond symptomatic effects: potential of donepezil as a neuroprotective agent and disease modifier in Alzheimer's disease. ( Dash, A; Hsu, JL; Kandiah, N; Kim, SH; Suthisisang, C; Udommongkol, C, 2017) |
| "Patients with vascular dementia (VaD) and Alzheimer's disease with cerebrovascular disease (AD + CVD) have dementia associated with underlying CVD." | 2.43 | Dementia with cerebrovascular disease: the benefits of early treatment. ( Schindler, RJ, 2005) |
| "Research into Alzheimer's disease (AD) pathology has identified several underlying disease processes that are potential targets for drug discovery and development." | 2.42 | NMDA receptor antagonists. A new therapeutic approach for Alzheimer's disease. ( Farlow, MR, 2004) |
| "Once the clinical diagnosis of Alzheimer's disease has been made, a treatment plan must be developed." | 2.41 | Guidelines for managing Alzheimer's disease: Part II. Treatment. ( Cherry, D; Cummings, JL; Frank, JC; Hewett, L; Kemp, B; Kohatsu, ND; Mittman, B, 2002) |
| "During the last years, treatment of Alzheimer's disease has improved following a better detection of this disease and, more importantly, following a better knowledge of its physiopathogeny." | 2.41 | [Anticholinesterase agents in Alzheimer's disease]. ( Sternon, J; Ventura, M, 2001) |
| "Diagnosing and treating patients with Alzheimer's disease (AD) at an early stage should improve the quality of life of the patient and caregiver." | 1.38 | An economic evaluation of early assessment for Alzheimer's disease in the United Kingdom. ( Blume, S; Getsios, D; Hernández, L; Ishak, KJ; Maclaine, G, 2012) |
| "Treatment with donepezil did not alter the progression of hippocampal deformation in subjects with DAT in this study." | 1.36 | Donepezil treatment and changes in hippocampal structure in very mild Alzheimer disease. ( Csernansky, JG; Galvin, JE; Harms, MP; Morris, JC; Staggs, JM; Wang, L; Xiong, C, 2010) |
| "Donepezil is a drug used for treatment in patients with Alzheimer's disease (AD)." | 1.35 | Cost-effectiveness analysis of donepezil for mild to moderate Alzheimer's disease in Taiwan. ( Fuh, JL; Wang, SJ, 2008) |
| "Available treatments for Alzheimer's disease (AD) need to be evaluated in order to determine whether the clinical benefits justify their additional costs." | 1.35 | Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease. ( García-Pérez, L; Hart, W; Linertová, R; López-Bastida, J, 2009) |
| "Hypersexuality in Alzheimer's disease (AD) has been rarely investigated." | 1.35 | Effect of citalopram in treating hypersexuality in an Alzheimer's disease case. ( Bruno, G; Lenzi, GL; Talarico, G; Tosto, G, 2008) |
| "donepezil) in Alzheimer's disease (AD)." | 1.34 | Cognitive stimulation therapy for Alzheimer's disease: the effect of cognitive stimulation therapy on the progression of mild Alzheimer's disease in patients treated with donepezil. ( Matsuda, O, 2007) |
| "Delayed disease progression and symptomatic improvement occur with cholinesterase inhibitors (ChEIs) in dementia with Lewy bodies (DLB)." | 1.33 | Emergent complications following donepezil switchover to galantamine in three cases of dementia with Lewy bodies. ( Bhanji, NH; Gauthier, S, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (5.21) | 18.2507 |
| 2000's | 54 (56.25) | 29.6817 |
| 2010's | 33 (34.38) | 24.3611 |
| 2020's | 4 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, SY | 1 |
| Cho, HY | 1 |
| Oh, JP | 1 |
| Park, J | 1 |
| Bae, SH | 1 |
| Park, H | 1 |
| Kim, EJ | 1 |
| Lee, JH | 1 |
| Honjo, Y | 1 |
| Ide, K | 1 |
| Takechi, H | 1 |
| Kim, GW | 1 |
| Kim, BC | 1 |
| Park, KS | 1 |
| Jeong, GW | 1 |
| Baik, K | 1 |
| Kim, SM | 1 |
| Jung, JH | 1 |
| Lee, YH | 1 |
| Chung, SJ | 1 |
| Yoo, HS | 1 |
| Ye, BS | 1 |
| Lee, PH | 1 |
| Sohn, YH | 1 |
| Kang, SW | 1 |
| Kang, SY | 1 |
| Kim, SH | 1 |
| Kandiah, N | 1 |
| Hsu, JL | 1 |
| Suthisisang, C | 1 |
| Udommongkol, C | 1 |
| Dash, A | 1 |
| Cavedo, E | 4 |
| Grothe, MJ | 2 |
| Colliot, O | 4 |
| Lista, S | 4 |
| Chupin, M | 4 |
| Dormont, D | 4 |
| Houot, M | 1 |
| Lehéricy, S | 3 |
| Teipel, S | 1 |
| Dubois, B | 5 |
| Hampel, H | 5 |
| Yoshii, F | 1 |
| Kawaguchi, C | 1 |
| Kohara, S | 1 |
| Shimizu, M | 1 |
| Onaka, H | 1 |
| Ryo, M | 1 |
| Takahashi, W | 1 |
| Di Santo, SG | 1 |
| Prinelli, F | 1 |
| Adorni, F | 1 |
| Caltagirone, C | 1 |
| Musicco, M | 1 |
| Ikeda, M | 2 |
| Mori, E | 4 |
| Kosaka, K | 2 |
| Iseki, E | 2 |
| Hashimoto, M | 3 |
| Matsukawa, N | 1 |
| Matsuo, K | 1 |
| Nakagawa, M | 2 |
| Omori, C | 1 |
| Kaneko, M | 1 |
| Nakajima, E | 1 |
| Akatsu, H | 1 |
| Waragai, M | 1 |
| Maeda, M | 1 |
| Morishima-Kawashima, M | 1 |
| Saito, Y | 2 |
| Nakaya, T | 1 |
| Taru, H | 1 |
| Yamamoto, T | 1 |
| Asada, T | 1 |
| Hata, S | 1 |
| Suzuki, T | 1 |
| Shoji, M | 1 |
| Li, M | 1 |
| Zheng, C | 1 |
| Kawada, T | 1 |
| Inagaki, M | 1 |
| Uemura, K | 1 |
| Sugimachi, M | 1 |
| Donohue, MC | 1 |
| Moghadam, SH | 1 |
| Roe, AD | 1 |
| Sun, CK | 1 |
| Edland, SD | 2 |
| Thomas, RG | 4 |
| Petersen, RC | 8 |
| Sano, M | 2 |
| Galasko, D | 2 |
| Aisen, PS | 6 |
| Rissman, RA | 2 |
| Meguro, K | 1 |
| Ouchi, Y | 1 |
| Akanuma, K | 1 |
| Meguro, M | 1 |
| Kasai, M | 1 |
| Croisile, B | 2 |
| Louis Tisserand, G | 1 |
| Touchon, J | 3 |
| Bonafe, A | 2 |
| Ousset, PJ | 2 |
| Ait Ameur, A | 1 |
| Rouaud, O | 2 |
| Ricolfi, F | 2 |
| Vighetto, A | 2 |
| Pasquier, F | 2 |
| Delmaire, C | 2 |
| Ceccaldi, M | 2 |
| Girard, N | 2 |
| Dufouil, C | 1 |
| Tonelli, I | 1 |
| Duveau, F | 2 |
| Garnero, L | 1 |
| Sarazin, M | 2 |
| Tamasaki, A | 1 |
| Ueda, R | 1 |
| Ohno, K | 1 |
| Yokoyama, K | 1 |
| Satake, T | 1 |
| Sakuma, H | 1 |
| Takahashi, Y | 1 |
| Kondoh, T | 1 |
| Maegaki, Y | 1 |
| Miyagishi, H | 1 |
| Yamaguchi, H | 1 |
| Teipel, SJ | 1 |
| Galluzzi, S | 2 |
| Bakardjian, H | 1 |
| Florian, H | 1 |
| Meier, A | 1 |
| Gauthier, S | 4 |
| Lipschitz, S | 1 |
| Lin, Y | 1 |
| Tang, Q | 1 |
| Othman, AA | 1 |
| Robieson, WZ | 1 |
| Gault, LM | 1 |
| Soysal, P | 1 |
| Isik, AT | 1 |
| De Beaumont, L | 1 |
| Pelleieux, S | 1 |
| Lamarre-Théroux, L | 1 |
| Dea, D | 1 |
| Poirier, J | 1 |
| Tisserand, GL | 1 |
| Sokolow, S | 1 |
| Li, X | 1 |
| Chen, L | 1 |
| Taylor, KD | 1 |
| Rotter, JI | 1 |
| Apostolova, LG | 1 |
| Ruis, J | 1 |
| Tosto, G | 1 |
| Talarico, G | 1 |
| Lenzi, GL | 1 |
| Bruno, G | 1 |
| van Straaten, EC | 1 |
| Harvey, D | 2 |
| Scheltens, P | 2 |
| Barkhof, F | 1 |
| Thal, LJ | 4 |
| Jack, CR | 2 |
| DeCarli, C | 2 |
| Irizarry, MC | 1 |
| Raman, R | 2 |
| Schwarzschild, MA | 1 |
| Becerra, LM | 1 |
| Peterson, RC | 1 |
| Ascherio, A | 1 |
| Knopman, DS | 1 |
| Doody, RS | 2 |
| Ferris, SH | 1 |
| Salloway, S | 1 |
| Sun, Y | 2 |
| Goldman, R | 1 |
| Watkins, WE | 1 |
| Xu, Y | 4 |
| Murthy, AK | 1 |
| López-Bastida, J | 1 |
| Hart, W | 1 |
| García-Pérez, L | 1 |
| Linertová, R | 1 |
| Kawahira, K | 1 |
| Noma, T | 1 |
| Iiyama, J | 1 |
| Etoh, S | 1 |
| Ogata, A | 1 |
| Shimodozono, M | 1 |
| Venneri, A | 1 |
| Lane, R | 2 |
| Hatoum, HT | 1 |
| Thomas, SK | 1 |
| Lin, SJ | 1 |
| Bullock, R | 1 |
| Lu, PH | 1 |
| Teng, E | 1 |
| Tingus, K | 1 |
| Cummings, JL | 2 |
| Nozawa, M | 1 |
| Ichimiya, Y | 1 |
| Nozawa, E | 1 |
| Utumi, Y | 1 |
| Sugiyama, H | 1 |
| Murayama, N | 1 |
| Arai, H | 2 |
| Wilkinson, D | 2 |
| Schindler, R | 3 |
| Schwam, E | 2 |
| Waldemar, G | 2 |
| Jones, RW | 1 |
| Lopez, OL | 2 |
| Cummings, J | 3 |
| Feldman, HH | 2 |
| Hanyu, H | 1 |
| Sato, T | 1 |
| Hirao, K | 1 |
| Kanetaka, H | 1 |
| Iwamoto, T | 2 |
| Koizumi, K | 1 |
| Wang, L | 1 |
| Harms, MP | 1 |
| Staggs, JM | 1 |
| Xiong, C | 1 |
| Morris, JC | 1 |
| Csernansky, JG | 1 |
| Galvin, JE | 1 |
| Kanaya, K | 1 |
| Abe, S | 1 |
| Sakai, M | 1 |
| Fujii, H | 1 |
| Panza, F | 1 |
| Frisardi, V | 1 |
| Capurso, C | 1 |
| D'Introno, A | 1 |
| Colacicco, AM | 1 |
| Chiloiro, R | 1 |
| Dellegrazie, F | 1 |
| Di Palo, A | 1 |
| Capurso, A | 1 |
| Solfrizzi, V | 1 |
| Whitehair, DC | 1 |
| Sherzai, A | 1 |
| Emond, J | 1 |
| Fleisher, AS | 2 |
| Jones, R | 1 |
| Zhang, R | 1 |
| Andrieu, S | 1 |
| Sampaio, C | 1 |
| Carrillo, M | 1 |
| Khachaturian, ZS | 1 |
| Siemers, E | 1 |
| Hendrix, SB | 1 |
| Grundman, M | 3 |
| Schneider, LS | 3 |
| Schindler, RJ | 2 |
| Salmon, E | 2 |
| Potter, WZ | 1 |
| Salmon, D | 1 |
| Donohue, M | 1 |
| Bednar, MM | 1 |
| Vellas, B | 1 |
| Getsios, D | 1 |
| Blume, S | 1 |
| Ishak, KJ | 1 |
| Maclaine, G | 1 |
| Hernández, L | 1 |
| Gustavsson, A | 1 |
| Jönsson, L | 1 |
| Parmler, J | 1 |
| Andreasen, N | 2 |
| Wattmo, C | 2 |
| Wallin, ÅK | 2 |
| Minthon, L | 2 |
| Massoud, F | 1 |
| Léger, GC | 1 |
| Atri, A | 1 |
| Stefanacci, RG | 1 |
| Seki, T | 1 |
| Kamiya, T | 1 |
| Furukawa, K | 1 |
| Azumi, M | 1 |
| Ishizuka, S | 1 |
| Takayama, S | 1 |
| Nagase, S | 1 |
| Yamakuni, T | 1 |
| Yaegashi, N | 1 |
| Pratt, RD | 1 |
| Borroni, B | 1 |
| Pettenati, C | 1 |
| Bordonali, T | 1 |
| Akkawi, N | 1 |
| Di Luca, M | 1 |
| Padovani, A | 2 |
| Geldmacher, DS | 1 |
| Provenzano, G | 1 |
| McRae, T | 2 |
| Mastey, V | 1 |
| Ieni, JR | 1 |
| Grossberg, GT | 1 |
| Corey-Bloom, J | 1 |
| Small, GW | 1 |
| Tariot, PN | 1 |
| Qizilbash, N | 1 |
| Courtney, C | 1 |
| Farrell, D | 1 |
| Gray, R | 1 |
| Hills, R | 1 |
| Lynch, L | 1 |
| Sellwood, E | 1 |
| Edwards, S | 1 |
| Hardyman, W | 1 |
| Raftery, J | 1 |
| Crome, P | 1 |
| Lendon, C | 1 |
| Shaw, H | 1 |
| Bentham, P | 1 |
| Farlow, MR | 1 |
| Rozzini, L | 1 |
| Ghianda, D | 1 |
| Trabucchi, M | 1 |
| Hirono, N | 1 |
| Ishii, K | 1 |
| Kazui, H | 2 |
| Matsumoto, K | 1 |
| Nakano, Y | 1 |
| Yasuda, M | 1 |
| Bennett, D | 1 |
| Doody, R | 2 |
| Ferris, S | 1 |
| Jin, S | 2 |
| Kaye, J | 1 |
| Levey, A | 1 |
| Pfeiffer, E | 1 |
| van Dyck, CH | 1 |
| Blacker, D | 1 |
| Lu, S | 1 |
| Hill, J | 1 |
| Fillit, H | 1 |
| Barnes, DE | 1 |
| Yaffe, K | 1 |
| Kirshner, HS | 1 |
| Bhanji, NH | 1 |
| Johannsen, P | 2 |
| Richardson, S | 2 |
| Qvitzau, S | 1 |
| Matsuda, O | 1 |
| Frisoni, GB | 1 |
| Clark, CM | 1 |
| Sowell, BB | 1 |
| Taylor, C | 1 |
| Gamst, AC | 1 |
| Eriksson, S | 1 |
| Båtsman, S | 1 |
| Nasman, B | 1 |
| Ekdahl, A | 1 |
| Kilander, L | 1 |
| Grut, M | 1 |
| Rydén, M | 1 |
| Wallin, A | 1 |
| Jonsson, M | 1 |
| Olofsson, H | 1 |
| Londos, E | 1 |
| Eriksdotter Jonhagen, M | 1 |
| Rose, DZ | 1 |
| Small, BJ | 1 |
| Gagnon, E | 1 |
| Robinson, B | 1 |
| Fuh, JL | 1 |
| Wang, SJ | 1 |
| Brodaty, H | 1 |
| Sachdev, P | 1 |
| Berman, K | 1 |
| Gibson, L | 1 |
| Kemp, NM | 1 |
| Cullen, B | 1 |
| Burns, A | 1 |
| Black, SE | 1 |
| Li, H | 1 |
| Jambor, KM | 1 |
| Perdomo, CA | 1 |
| Bruera, E | 1 |
| El Osta, B | 1 |
| Valero, V | 1 |
| Driver, LC | 1 |
| Pei, BL | 1 |
| Shen, L | 1 |
| Poulter, VA | 1 |
| Palmer, JL | 1 |
| Tei, E | 1 |
| Yamamoto, H | 1 |
| Watanabe, T | 1 |
| Miyazaki, A | 1 |
| Nakadate, T | 1 |
| Kato, N | 1 |
| Mimura, M | 1 |
| Green, C | 1 |
| Neno, R | 1 |
| Jakovljevic, M | 1 |
| Vuksan-Cusa, B | 1 |
| Topic, R | 1 |
| Hager, K | 1 |
| Kenklies, M | 1 |
| McAfoose, J | 1 |
| Engel, J | 1 |
| Münch, G | 1 |
| Morrison, LJ | 1 |
| Liao, S | 1 |
| Singh, D | 1 |
| Forlano, R | 1 |
| Athey, R | 1 |
| Bourke, D | 1 |
| Druckenbrod, RW | 1 |
| Stewart, A | 1 |
| Phillips, R | 1 |
| Dempsey, G | 1 |
| Neumann, PJ | 2 |
| Hermann, RC | 1 |
| Kuntz, KM | 1 |
| Araki, SS | 1 |
| Duff, SB | 1 |
| Leon, J | 1 |
| Berenbaum, PA | 1 |
| Goldman, PA | 1 |
| Williams, LW | 1 |
| Weinstein, MC | 2 |
| McLendon, BM | 1 |
| Doraiswamy, PM | 1 |
| Claxton, K | 1 |
| Araki, S | 1 |
| Ventura, M | 1 |
| Sternon, J | 1 |
| Frank, JC | 1 |
| Cherry, D | 1 |
| Kohatsu, ND | 1 |
| Kemp, B | 1 |
| Hewett, L | 1 |
| Mittman, B | 1 |
| Robert, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multi-targets, Single-lead GPi+NBM DBS in Parkinson's Disease With Mild Cognitive Impairment[NCT04571112] | 6 participants (Actual) | Interventional | 2017-12-04 | Completed | |||
| Open Label Study for the Use of Tyrosine Kinase Inhibitors for Treatment of Cognitive Decline Due to Degenerative Dementias[NCT02921477] | Phase 1 | 150 participants (Anticipated) | Interventional | 2016-09-30 | Enrolling by invitation | ||
| Assessment of the Comparative Effect of Donepezil 10mg/d and Placebo on Clinical and Radiological Markers in Patients With Mild Cognitive Disorders[NCT00403520] | Phase 4 | 240 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors[NCT01549834] | Phase 2 | 434 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| Long-Term Safety and Tolerability of ABT-126 in Adults With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: An Open-Label Extension Study for Subjects Completing Study M11-793[NCT01690195] | Phase 2 | 343 participants (Actual) | Interventional | 2012-09-30 | Terminated (stopped due to Data obtained from the M11-428 study is not critical to the continued evaluation of ABT-126.) | ||
| Effects of Combined Memantine (Namenda) Plus Escitalopram (Lexapro) Treatment in Elderly Depressed Patients With Cognitive Impairment[NCT01876823] | Phase 2/Phase 3 | 60 participants (Actual) | Interventional | 2006-04-30 | Completed | ||
| Neurofeedback as a Novel Treatment for Mild Cognitive Impairment & Early Alzheimer's[NCT02987842] | 30 participants (Anticipated) | Interventional | 2016-12-31 | Not yet recruiting | |||
| A 6 Months, Prospective, Open-label, Observational, Non-interventional Clinical Trial to Examine the Efficacy and Safety of Donepezil (Dementis®) Administration in Patients With Dementia.[NCT01772095] | 389 participants (Actual) | Observational | 2013-02-28 | Completed | |||
| A Randomized, Double-Blind, Placebo-Controlled Trial of Vitamin E and Donepezil HCL (Aricept) to Delay Clinical Progression From Mild Cognitive Impairment (MCI) to Alzheimer's Disease (AD)[NCT00000173] | Phase 3 | 0 participants | Interventional | 1999-03-31 | Completed | ||
| A 36-month, Multi-centre, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment (MCI)[NCT01429623] | Phase 2 | 210 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
| Statin Therapy To Limit Cognitive Dysfunction After Cardiac Surgery[NCT01186289] | 0 participants (Actual) | Interventional | 2010-10-31 | Withdrawn (stopped due to Principal Investigator decided not to pursue enrollment due to changes in standard of care.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in 24-item Hamilton Rating Scale for Depression (HAMD) scores from baseline to Week 48: HAMD measures depression severity based on a series of 24 items items. The range of HAMD total score is 0-74; 0 indicates no depressive symptoms and a maximum HAMD score is a 74, where the greater the score indicates more significant psychopathology. In this study, moderate to severe depression is considered a HAMD-24 greater than 14. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | scores on a scale (Mean) |
|---|---|
| Es-citalopram and Memantine Treatment | -15.2 |
Change in Selective Reminding Test-Delayed Recall scores from baseline to Week 48: SRT Delay is administered 15 minutes after the immediate recall portion. Patients are asked to remember as many of the words as they can from the 6 trials. Maximum raw score is a 12 for free recall. If a patient is unable to recall a word, they are given a chance to recognize it among three incorrect word choices. Maximum raw score for recognition is 12. The greater the score on the delayed recall portion, the better the patient does on the assessment. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | units on a scale (Mean) |
|---|---|
| Es-citalopram and Memantine Treatment | 1.2 |
Change in Selective Reminding Test-Total Immediate Recall (SRT-IR) scores from baseline to Week 48: Measures word recall (maximum 12 words per trial, across 6 trials). Maximum total recall score across 6 trials is 72; minimum recall is 0 across 6 trials. The higher the raw score, the better the patient did at recalling the target words. The unit of measure is the raw score, or the sum of the number of words recalled across all 6 trials. (NCT01876823)
Timeframe: baseline, 48 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Es-citalopram and Memantine Treatment | 7.5 |
Change in Trails A scores from baseline to Week 48: Measures attention and executive function. It asks patients to connect numbers from 1-25 in numerical order as fast as they can. Patients are timed; the longer it takes for the patient to connect the numbers, the worse their score. Unit of measure is in seconds. The amount of errors that the patient makes during trails is also recorded. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | seconds (Mean) |
|---|---|
| Es-citalopram and Memantine Treatment | 1.9 |
Change from baseline to Week 48 on Trails B: Measures attention and executive function. It asks patients to connect numbers and letters in numerical to alphabetical order from (1-13 and A-L) as fast as they can. Patients are timed; the longer it takes for the patient to connect the numbers and letters, the worse their score. Unit of measure is in seconds. The amount of errors that the patient makes during trails is also recorded. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | seconds (Mean) |
|---|---|
| Es-citalopram and Memantine Treatment | -36.3 |
Change in Wechsler Memory Scale-III scores from baseline to Week 48: The WMS-III Visual Reproduction sub-test was used to measure visual working memory and delayed memory. Patients were shown pictures of four drawings and were asked to reproduce them from memory immediately after seeing them, and 25 minutes after seeing them. The four scores are summed and the greater the total raw score, the better the patient did on the assessment. The maximum raw score for this test is a 41 on both the immediate and delayed portions (the overall range is 0-82 points). The change score is calculated using the total scores of both the immediate and delayed portions. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | units on a scale (Mean) |
|---|---|
| Es-citalopram and Memantine Treatment | 9.9 |
The CDR is a numeric rating scale that is used to quantify the severity of one's cognitive function. The scale goes from 0=normal; 0.5=mild cognitive impairment; 1 to 3=mild to moderate/severe dementia. CDR was used a dichotomous outcome measure (no=0; yes=1). (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | participants (Number) |
|---|---|
| Es-citalopram and Memantine Treatment | 1 |
The CGI Cognitive Change follows a seven-point likert scale. Compared to the patient's condition at baseline in the study [prior to medication initiation], the patient's condition is rated as: 1=very much improved since the initiation of treatment; 2=much improved; 3=minimally improved; 4=no change from baseline (the initiation of treatment); 5=minimally worse; 6= much worse; 7=very much worse since the initiation of treatment. Responses from the entire group were calculated. Mean at final visit and baseline is reported below. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | units on a scale (Mean) | |
|---|---|---|
| CGI-Cognitive Change (Baseline) | Clinical Global Impression-Cogntive Change (WK 48) | |
| Es-citalopram and Memantine Treatment | 3.6 | 2.7 |
The CGI Depression Change follows a seven-point likert scale. Compared to the patient's condition at baseline in the study [prior to medication initiation], the patient's condition is rated as: 1=very much improved since the initiation of treatment; 2=much improved; 3=minimally improved; 4=no change from baseline (the initiation of treatment); 5=minimally worse; 6= much worse; 7=very much worse since the initiation of treatment. Responses were calculated for the entire group. Mean at final visit has been reported below. Higher mean at baseline indicates a decrease in depression scores. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Cognitive Global Impression at Baseline | Cognitive Global Impression at Final Visit (WK 48) | |
| Es-citalopram and Memantine Treatment | 4.1 | 2.1 |
"Somatic side effect rating scale which includes 26 common somatic side effects associated with previous medication clinical trials; rated by the study physician. Factors were dichotomized to yes or no responses on this scale, which equated to the symptom being either present or not present. Yes and no responses were given a value of 0 (no) or 1 (yes). Responses from the entire group were calculated and the mean at baseline and the last visit is reported below." (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Treatment Emergent Side Effects (Baseline) | Treatment Emergent Side Effects (WK 48) | |
| Es-citalopram and Memantine Treatment | 6.6 | 3.2 |
Mean value change (from baseline) in Disability Assessment in Dementia (DAD) across entire study period. DAD evaluates the basic and instrumental activities in daily activities of elderly people with dementia. Higher scores reflect better functioning. DAD ranges from 0 to 100. (NCT01429623)
Timeframe: 3,6,12,18,24,30 and 36 months
| Intervention | Change from basline on units on a scale (Mean) |
|---|---|
| Ladostigil Hemitartrate | -0.77 |
| Placebo Control | -0.40 |
"Mean value change (from baseline) in Geriatric Depression Scale (GDS) across entire study period. The GDS ranges from 0 to 30. Scores of 0-9 are considered normal, 10-19 mildly depressed, and 20-30 severely depressed." (NCT01429623)
Timeframe: 3,6,12,18,24,30 and 36 months
| Intervention | Change from basline on units on a scale (Mean) |
|---|---|
| Ladostigil Hemitartrate | .084 |
| Placebo Control | .242 |
Mean value change (from baseline) in Neuropsychiatric Test Battery (NTB) across entire study period. The NTB included the following well known cognitive tests: Rey Auditory Verbal Learning Test (RAVLT), Controlled Word Association Test (COWAT), Category Fluency Test (CFT), WMS-R Digit Span, and Trail Making Part A and B. The mean value was comprised of the z score of each of these tests with all z scores in the direction of higher scores better functioning. Range -3 to +3. (NCT01429623)
Timeframe: 3,6,12,18,24,30 and 36 months
| Intervention | Change from basline on units on a scale (Mean) |
|---|---|
| Ladostigil Hemitartrate | .21 |
| Placebo Control | .17 |
"Total number of conversions from Mild Cognitive Impairment to Alzheimer's disease across entire 3 year study period. Conversion is determined, or defined, by a Clinical Dementia Rating (CDR) score of greater than or equal to one.~Composite rating ranges from 0 no symptoms of dementia to 3 Severe symptoms of dementia." (NCT01429623)
Timeframe: 3,6,12,18,24,30 and 36 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ladostigil Hemitartrate | 14 |
| Placebo Control | 21 |
18 reviews available for donepezil and Disease Exacerbation
| Article | Year |
|---|---|
Beyond symptomatic effects: potential of donepezil as a neuroprotective agent and disease modifier in Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Disease Progression; Donepezil; Early Diagnos | 2017 |
A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Behavior; Cholinesterase Inhibitors; Cognition; Data Interpretation, Statis | 2013 |
[Programs for continuing medical education: a session; 3. Dementia: diagnosis and therapy].
Topics: Alzheimer Disease; Amyloid beta-Peptides; Biomarkers; Cholinesterase Inhibitors; Cognitive Dysfuncti | 2014 |
Predicting cognitive decline in Alzheimer's disease: an integrated analysis.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Disease | 2010 |
Pharmacological treatment of Alzheimer disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Disease Progression; Donepezil; Galantamine; Humans; I | 2011 |
Effective pharmacological management of Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Dementia; Disease Progression; Donepezil; G | 2011 |
The costs of Alzheimer's disease and the value of effective therapies.
Topics: Age Factors; Aging; Alzheimer Disease; Cholinesterase Inhibitors; Disease Progression; Donepezil; Ga | 2011 |
Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease.
Topics: Alkaloids; Alzheimer Disease; Amino Acids; Animals; Cholinesterase Inhibitors; Dietary Supplements; | 2012 |
NMDA receptor antagonists. A new therapeutic approach for Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Disease Progression; Donepezil; Excitatory Amino Acid | 2004 |
Dementia with cerebrovascular disease: the benefits of early treatment.
Topics: Cerebrovascular Disorders; Cholinesterase Inhibitors; Clinical Trials as Topic; Dementia, Vascular; | 2005 |
[Medical treatment of Alzheimer's disease].
Topics: Activities of Daily Living; Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; | 2006 |
Early identification of cognitive deficits: preclinical Alzheimer's disease and mild cognitive impairment.
Topics: Adult; Alzheimer Disease; Cognition Disorders; Disease Progression; Donepezil; Humans; Indans; Neuro | 2007 |
Modelling disease progression in Alzheimer's disease: a review of modelling methods used for cost-effectiveness analysis.
Topics: Alzheimer Disease; Cost-Benefit Analysis; Disease Progression; Donepezil; Galantamine; Humans; Indan | 2007 |
Pharmacotherapy for people with Alzheimer's disease: a Markov-cycle evaluation of five years' therapy using donepezil.
Topics: Aged; Alzheimer Disease; Cognition Disorders; Cost-Benefit Analysis; Disease Progression; Donepezil; | 1998 |
Defining meaningful change in Alzheimer's disease trials: the donepezil experience.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Disease Progression; Donepe | 1999 |
[Anticholinesterase agents in Alzheimer's disease].
Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Carbamates; Cholinesterase | 2001 |
Guidelines for managing Alzheimer's disease: Part II. Treatment.
Topics: Advance Directives; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Disease Progression; D | 2002 |
Understanding and managing behavioural symptoms in Alzheimer's disease and related dementias: focus on rivastigmine.
Topics: Acetylcholine; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Cognitive Behavioral Therap | 2002 |
29 trials available for donepezil and Disease Exacerbation
| Article | Year |
|---|---|
Reduced basal forebrain atrophy progression in a randomized Donepezil trial in prodromal Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Atrophy; Basal Forebrain; Cholinergic Neurons; Disease Progression; Donepez | 2017 |
Long-term safety and efficacy of donepezil in patients with dementia with Lewy bodies: results from a 52-week, open-label, multicenter extension study.
Topics: Aged; Aged, 80 and over; Data Interpretation, Statistical; Disease Progression; Donepezil; Double-Bl | 2013 |
Longitudinal plasma amyloid beta in Alzheimer's disease clinical trials.
Topics: Aged; Alzheimer Disease; Amyloid beta-Peptides; Apolipoprotein E4; Biomarkers; Blood Chemical Analys | 2015 |
Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Atrophy; Disease Progression; Donepezil; Double-Blind Method; Female; Franc | 2015 |
Effects of Donepezil on Extrapyramidal Symptoms in Patients with Dementia with Lewy Bodies: A Secondary Pooled Analysis of Two Randomized-Controlled and Two Open-Label Long-Term Extension Studies.
Topics: Aged; Aged, 80 and over; Cholinesterase Inhibitors; Datasets as Topic; Disease Progression; Donepezi | 2015 |
Predictors of cognitive decline and treatment response in a clinical trial on suspected prodromal Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognitive Dysfunction; Cross-Sectional Studies; Disease | 2016 |
Predictors of cognitive decline and treatment response in a clinical trial on suspected prodromal Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognitive Dysfunction; Cross-Sectional Studies; Disease | 2016 |
Predictors of cognitive decline and treatment response in a clinical trial on suspected prodromal Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognitive Dysfunction; Cross-Sectional Studies; Disease | 2016 |
Predictors of cognitive decline and treatment response in a clinical trial on suspected prodromal Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognitive Dysfunction; Cross-Sectional Studies; Disease | 2016 |
Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; D | 2016 |
Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; D | 2016 |
Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; D | 2016 |
Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; D | 2016 |
Butyrylcholinesterase K and Apolipoprotein E-ɛ4 Reduce the Age of Onset of Alzheimer's Disease, Accelerate Cognitive Decline, and Modulate Donepezil Response in Mild Cognitively Impaired Subjects.
Topics: Age of Onset; Aged; Aged, 80 and over; Alzheimer Disease; Apolipoprotein E4; Butyrylcholinesterase; | 2016 |
Reduced Regional Cortical Thickness Rate of Change in Donepezil-Treated Subjects With Suspected Prodromal Alzheimer's Disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amnesia; Cerebral Cortex; Cognitive Dysfunction; Disease | 2016 |
Periventricular white matter hyperintensities increase the likelihood of progression from amnestic mild cognitive impairment to dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amnesia; Antioxidants; Atrophy; Brain; Cerebral Ventricl | 2008 |
Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Disease | 2009 |
Donepezil delays progression to AD in MCI subjects with depressive symptoms.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antioxidants; Brain; Cholinesterase Inhibitors; Cognitio | 2009 |
Clinical effects of high oral dose of donepezil for patients with Alzheimer's disease in Japan.
Topics: Aged; Alzheimer Disease; Apolipoprotein E4; Cholinesterase Inhibitors; Cognition; Disease Progressio | 2009 |
Effectiveness of donepezil in reducing clinical worsening in patients with mild-to-moderate alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Disease Progression; Donepezil; Double-Blind Method; Fem | 2009 |
The progression of cognitive deterioration and regional cerebral blood flow patterns in Alzheimer's disease: a longitudinal SPECT study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain Mapping; Cerebral Arteries; Cerebral Cortex; Cereb | 2010 |
Patient populations in clinical trials of the efficacy and tolerability of donepezil in patients with vascular dementia.
Topics: Aged; Brain; Cerebrovascular Circulation; Cognition; Cohort Studies; Dementia, Vascular; Disease Pro | 2002 |
Serum cholesterol levels modulate long-term efficacy of cholinesterase inhibitors in Alzheimer disease.
Topics: Aged; Alzheimer Disease; Apolipoproteins E; Carbamates; Cholesterol; Cholinesterase Inhibitors; Dise | 2003 |
Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Disease Progression; Donepezil; Double-Blind Met | 2003 |
Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; C | 2004 |
Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease?
Topics: Aged; Alzheimer Disease; Apolipoproteins E; Atrophy; Cholinesterase Inhibitors; Cohort Studies; Dise | 2005 |
Vitamin E and donepezil for the treatment of mild cognitive impairment.
Topics: Alzheimer Disease; Apolipoprotein E4; Apolipoproteins E; Cholinesterase Inhibitors; Cognition Disord | 2005 |
Assessing therapeutic efficacy in a progressive disease: a study of donepezil in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Cognition; Disease Progression; Do | 2006 |
Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia.
Topics: Aged; Aged, 80 and over; Atrophy; Cognition Disorders; Dementia; Disease Progression; Donepezil; Dou | 2007 |
Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia.
Topics: Aged; Aged, 80 and over; Atrophy; Cognition Disorders; Dementia; Disease Progression; Donepezil; Dou | 2007 |
Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia.
Topics: Aged; Aged, 80 and over; Atrophy; Cognition Disorders; Dementia; Disease Progression; Donepezil; Dou | 2007 |
Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia.
Topics: Aged; Aged, 80 and over; Atrophy; Cognition Disorders; Dementia; Disease Progression; Donepezil; Dou | 2007 |
Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment.
Topics: Age Distribution; Aged; Aged, 80 and over; Alzheimer Disease; Amnesia; Antioxidants; Apolipoprotein | 2007 |
Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognition; Disease Progression; Donepezil; Female; Human | 2007 |
Donepezil preserves cognition and global function in patients with severe Alzheimer disease.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Caregivers; Cholinesterase I | 2007 |
Donepezil for cancer fatigue: a double-blind, randomized, placebo-controlled trial.
Topics: Aged; Disease Progression; Donepezil; Double-Blind Method; Fatigue; Female; Humans; Indans; Male; Mi | 2007 |
Alpha-lipoic acid as a new treatment option for Alzheimer's disease--a 48 months follow-up analysis.
Topics: Aged; Alzheimer Disease; Antioxidants; Cholinesterase Inhibitors; Cognition Disorders; Disease Progr | 2007 |
Defining meaningful change in Alzheimer's disease trials: the donepezil experience.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Disease Progression; Donepe | 1999 |
50 other studies available for donepezil and Disease Exacerbation
| Article | Year |
|---|---|
Therapeutic Effects of Combination of Nebivolol and Donepezil: Targeting Multifactorial Mechanisms in ALS.
Topics: Amyotrophic Lateral Sclerosis; Animals; Disease Models, Animal; Disease Progression; Donepezil; HeLa | 2023 |
Medical interventions suppressed progression of advanced Alzheimer's disease more than mild Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Disease Progressio | 2020 |
A pilot study of brain morphometry following donepezil treatment in mild cognitive impairment: volume changes of cortical/subcortical regions and hippocampal subfields.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain; Cerebral Cortex; Cognitive Dysfunction; Disease P | 2020 |
Donepezil for mild cognitive impairment in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Cholinesterase Inhibitors; Cognitive Dysfunction; Disease Progressio | 2021 |
Characteristic deterioration of ADAS-Jcog subscale scores and correlations with regional cerebral blood flow reductions in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain; Cerebrovascular Circulation; Cognition; Cysteine; | 2018 |
Increased levels of plasma p3-alcα35, a major fragment of Alcadeinα by γ-secretase cleavage, in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid Precursor Protein Secretases; Biomarkers; Calciu | 2014 |
Adding the acetylcholinesterase inhibitor, donepezil, to losartan treatment markedly improves long-term survival in rats with chronic heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cholinesterase Inhibitors; Chronic Disease; Diseas | 2014 |
Donepezil can improve daily activities and promote rehabilitation for severe Alzheimer's patients in long-term care health facilities.
Topics: Activities of Daily Living; Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Disease Progress | 2014 |
Effects of donepezil and serotonin reuptake inhibitor on acute regression during adolescence in Down syndrome.
Topics: Adolescent; Brain; Disease Progression; Donepezil; Down Syndrome; Electroencephalography; Humans; In | 2016 |
Effects of Acetylcholinesterase Inhibitors on Nutritional Status in Elderly Patients with Dementia: A 6-month Follow-up Study.
Topics: Acetylcholinesterase; Activities of Daily Living; Aged; Body Mass Index; Body Weight; Cholinesterase | 2016 |
Deleterious Effect of Butyrylcholinesterase K-Variant in Donepezil Treatment of Mild Cognitive Impairment.
Topics: Aged; Aged, 80 and over; Apolipoprotein E4; Butyrylcholinesterase; Cholinesterase Inhibitors; Cognit | 2017 |
[Alzheimer type dementia].
Topics: Alzheimer Disease; Apolipoprotein E4; Diagnosis, Differential; Disease Progression; Donepezil; Human | 2008 |
Effect of citalopram in treating hypersexuality in an Alzheimer's disease case.
Topics: Alzheimer Disease; Brain; Citalopram; Cognition Disorders; Disease Progression; Donepezil; Fluorodeo | 2008 |
Plasma urate and progression of mild cognitive impairment.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Boston; Cognition Disorders; Confounding Factors, Epidem | 2009 |
Cracking the therapeutic nut in mild cognitive impairment: better nuts and better nutcrackers.
Topics: Alzheimer Disease; Biomarkers; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disord | 2009 |
Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cost-Benefit Analysis; Disease Progression; Donepezil; | 2009 |
Improvements in limb kinetic apraxia by repetition of a newly designed facilitation exercise in a patient with corticobasal degeneration.
Topics: Activities of Daily Living; Apraxia, Ideomotor; Cholinesterase Inhibitors; Disease Progression; Done | 2009 |
Effects of cholinesterase inhibition on brain white matter volume in Alzheimer's disease.
Topics: Acetylcholinesterase; Aged; Aged, 80 and over; Alzheimer Disease; Brain; Brain Mapping; Cholinestera | 2009 |
Predicting time to nursing home placement based on activities of daily living scores--a modelling analysis using data on Alzheimer's disease patients receiving rivastigmine or donepezil.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; D | 2009 |
Donepezil treatment and changes in hippocampal structure in very mild Alzheimer disease.
Topics: Aged; Alzheimer Disease; Atrophy; Brain Mapping; Cholinesterase Inhibitors; Cognition Disorders; Coh | 2010 |
Changes in cognitive functions of patients with dementia of the Alzheimer type following long-term administration of donepezil hydrochloride: relating to changes attributable to differences in apolipoprotein E phenotype.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Apolipoproteins E; Brief Psychiatric Rating Scale; Cogni | 2010 |
Effect of donepezil on the continuum of depressive symptoms, mild cognitive impairment, and progression to dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognition Disorders; Depressive Disorder; Disease Progre | 2010 |
Influence of apolipoprotein E varepsilon4 on rates of cognitive and functional decline in mild cognitive impairment.
Topics: Aged; Aged, 80 and over; Apolipoprotein E4; Cholinesterase Inhibitors; Cognition Disorders; Disease | 2010 |
Report of the task force on designing clinical trials in early (predementia) AD.
Topics: Advisory Committees; Alzheimer Disease; Amyloidogenic Proteins; Biomarkers; Clinical Trials as Topic | 2011 |
An economic evaluation of early assessment for Alzheimer's disease in the United Kingdom.
Topics: Alzheimer Disease; Caregivers; Cognition Disorders; Cost-Benefit Analysis; Disease Progression; Done | 2012 |
Disease progression and costs of care in Alzheimer's disease patients treated with donepezil: a longitudinal naturalistic cohort.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Cognition; Disease Progression; Donepezil; Fema | 2012 |
Nobiletin-rich Citrus reticulata peels, a kampo medicine for Alzheimer's disease: a case series.
Topics: Aged; Alzheimer Disease; Antioxidants; Chromatography, High Pressure Liquid; Citrus; Disease Progres | 2013 |
Academic highlights: emerging therapeutic strategies in Alzheimer's disease.
Topics: Alzheimer Disease; Brain; Combined Modality Therapy; Diagnosis, Differential; Disease Progression; D | 2004 |
Delay in nursing home placement with donepezil.
Topics: Aged; Alzheimer Disease; Bias; Cholinesterase Inhibitors; Data Interpretation, Statistical; Disease | 2004 |
Severe worsening of parkinsonism in Lewy body dementia due to donepezil.
Topics: Acetylcholine; Aged; Basal Ganglia; Cholinesterase Inhibitors; Disease Progression; Donepezil; Dopam | 2004 |
One-year change in cerebral glucose metabolism in patients with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Brain Chemistry; Brain Mapping; Disease Progression; Donepezil; Female; Flu | 2004 |
Mild cognitive impairment--no benefit from vitamin E, little from donepezil.
Topics: Alzheimer Disease; Apolipoprotein E4; Apolipoproteins E; Cholinesterase Inhibitors; Cognition Disord | 2005 |
Impact of donepezil use in routine clinical practice on health care costs in patients with Alzheimer's disease and related dementias enrolled in a large medicare managed care plan: a case-control study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Case-Control Studies; Cholinesterase Inhibitors; Dementi | 2005 |
Vitamin E and donepezil for the treatment of mild cognitive impairment.
Topics: Alzheimer Disease; Apolipoprotein E4; Apolipoproteins E; Cholinesterase Inhibitors; Data Interpretat | 2005 |
Mild cognitive impairment: to treat or not to treat.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Disease | 2005 |
Emergent complications following donepezil switchover to galantamine in three cases of dementia with Lewy bodies.
Topics: Aged; Cholinesterase Inhibitors; Disease Progression; Donepezil; Galantamine; Humans; Indans; Lewy B | 2005 |
Cognitive stimulation therapy for Alzheimer's disease: the effect of cognitive stimulation therapy on the progression of mild Alzheimer's disease in patients treated with donepezil.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognitive Behavioral Therapy; Combined Modality | 2007 |
Drug may slow brain shrinkage in pre-Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Atrophy; Brain; Cognition Disorders; Disease Progression; Donepezil; Humans | 2006 |
Primary progressive aphasia.
Topics: Aphasia, Primary Progressive; Cholinesterase Inhibitors; Disease Progression; Donepezil; Humans; Ind | 2007 |
Cost-effectiveness analysis of donepezil for mild to moderate Alzheimer's disease in Taiwan.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Disease Progression; Donepezil; Drug Costs; Fema | 2008 |
Do extrapyramidal features in Alzheimer patients treated with acetylcholinesterase inhibitors predict disease progression?
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cohort Studies; Disease Progr | 2007 |
Use of serum insulin-like growth factor-I levels to predict psychiatric non-response to donepezil in patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Disease Progression; Donepezi | 2008 |
NICE judgement leaves behind a nasty taste.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Disease Progression; Donepezil; Formularies as Topic; | 2007 |
Some treatment dilemmas in rapidly developing dementia: a case report.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Cholinesterase Inhibitors; Dementia; Depression; Diseas | 2008 |
Dementia medications in palliative care #174.
Topics: Antiparkinson Agents; Cholinesterase Inhibitors; Dementia; Disease Progression; Donepezil; Galantami | 2008 |
Neuroleptic malignant syndrome and catatonia in a patient with dementia.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Catatonia; Chlorpromazine; Choline | 2008 |
Possible association between donepezil and worsening Parkinson's disease.
Topics: Aged; Aged, 80 and over; Cholinesterase Inhibitors; Disease Progression; Donepezil; Female; Humans; | 1998 |
Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cost-Benefit Analysis; Costs and Cost Analysis; Diseas | 1999 |
Calculation of the natural history line in the long-term extension trial and the use of the 'intent-to-treat' (ITT) principle in donepezil treatment.
Topics: Alzheimer Disease; Bias; Disease Progression; Donepezil; Humans; Indans; Nootropic Agents; Piperidin | 1999 |
Bayesian value-of-information analysis. An application to a policy model of Alzheimer's disease.
Topics: Alzheimer Disease; Bayes Theorem; Cost-Benefit Analysis; Decision Theory; Disease Progression; Donep | 2001 |